Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
For the delivery of drugs into the brain, the use of nanoparticles as carriers has been described as a promising approach. Here, we prepared nanoparticles as carriers for the model drugs thioflavin T and thioflavin S that bind fibrillar amyloid β peptides (Aβ). These polymer colloids are composed of a polystyrene core and a degradable PBCA [poly(butyl‐2‐cyanoacrylate)] shell with a diameter of 90–100 nm as shown by dynamic light scattering. Fluorescence spectrophotometric analysis revealed that encapsulated thioflavin T exhibited significantly stronger fluorescence than the free fluorophore. The enzymatic degradation of core‐shell nanoparticles, as required in vivo, was shown after their treatment with porcine liver esterase, a non‐specific esterase, in vitro. Shells of nanoparticles were dose‐dependently degraded while their polystyrene cores remained intact. In the cortices of 7–14 months old APP/PS1 mice with age‐dependent β‐amyloidosis, thioflavins selectively targeted fibrillar Aβ after biodegradation‐induced release from their nanoparticulate carriers upon intracerebral injection. Collectively, our data suggest that core‐shell nanoparticles with controlled degradation in vivo can become versatile tools to trace and clear Aβ in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 5×
“We thank Drs. Joanna L. Jankowsky and David Borchelt (Department of Pathology, Johns Hopkins University, Balti- more, MD, USA), the colony founders of both APPswe/PS1dE9 and APPswe/PS1(A246E) mouse strains.”
MethodInfluentialOligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 4×
“The passage of the BBB by drugs is known to be an obstacle treating brain diseases (Kreuter, 2001; Duncan, 2003; Tuma and Hubbard, 2003).”
BackgroundInfluentialBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 3×
“Adsorption of apolipoprotein E onto nanoparticles facilitated the brain targeting of the model drug dalargin (Kreuter et al., 2002) while liposomes coated with an apolipoprotein peptide fragment considerably improved their internalisation by endothelial cells in vitro (Sauer et al.”
BackgroundTranscytosis: Crossing Cellular Barriers
TUMA, P. L., & HUBBARD, A. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00001.2003 · Cited by 681 · cited 2×
“The passage of the BBB by drugs is known to be an obstacle treating brain diseases (Kreuter, 2001; Duncan, 2003; Tuma and Hubbard, 2003).”
BackgroundDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561 · cited 2×
“While plaques containing fibrillar Ab may compromise synaptic integrity (Stern et al., 2004; Tsai et al., 2004), small, soluble oligomers of Ab are readily neurotoxic (Klein et al.”
BackgroundKlunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01232-2 · Cited by 457
Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443 · cited 1×
“Therefore, Ab is a prime target of pharmacological interventions in AD (Harkany et al., 2000; Mager et al., 2002; Conway et al., 2003).”
BackgroundGender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice
Wang, J., Tanila, H., Puoliväli, J., Kadish, I., & Groen, T. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.009 · Cited by 316
Self-citationEmerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Conway, K., Baxter, E., Felsenstein, K., & Reitz, A. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033391649 · Cited by 40
Cited by
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Core/shell nanoparticles in biomedical applications
Chatterjee, K., Sarkar, S., Jagajjanani Rao, K., & Paria, S. (2014) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2013.12.008 · Cited by 610
Nanoparticles in modern medicine: state of the art and future challenges.
(2007) · PubMed Central · Cited by 484
Nanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
Brambilla, D., Le Droumaguet, B., Nicolas, J., Hashemi, S. H., Wu, L.-P., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 294
Metadata
- Authors
- Siegemund, T., Paulke, B. ‐., Schmiedel, H., Bordag, N., Hoffmann, A., Harkany, T., Tanila, H., Kacza, J., & Härtig, W.
- Venue
- International Journal of Developmental Neuroscience
- Publisher
- Wiley
- Published
- 2005-12-28
- Volume
- 24
- Issue
- 2-3
- Pages
- 195-201
- ISSN
- 0736-5748 (ISSN-L)
- 1873-474X
- OpenAlex
- W2036648087
- Cited by
- 59
- References
- 13
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.